These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7517078)

  • 1. The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro.
    Yoshimura N; Ohmoto Y; Yasui H; Ohsaka Y; Bong JM; Kobayashi Y; Oka T
    Transplantation; 1994 Jun; 57(12):1815-8. PubMed ID: 7517078
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms of action of immunosuppressive agents: cyclosporin A, FK506, and rapamycin.
    Bierer BE
    Proc Assoc Am Physicians; 1995 Apr; 107(1):28-40. PubMed ID: 8630742
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of cyclosporine on interleukin 1(beta) and immunoglobulin production in vitro.
    Yoshimura N; Ohmoto Y; Yasui H; Ohsaka Y; Oka T
    Transplant Proc; 1994 Oct; 26(5):2845. PubMed ID: 7940896
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation.
    Wu J; Palladino MA; Figari IS; Morris RE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):238-40. PubMed ID: 1703683
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of rapamycin on the in vitro release of soluble interleukin-2 receptor by phytohemagglutinin, phorbol myristate acetate, and ionomycin-activated peripheral blood mononuclear cells.
    Barkis I; Hadjiyannaki-Koniavitou K; Vareltzides A; Hornung N; Raskova J; Degiannis D
    Transplant Proc; 1995 Feb; 27(1):432-4. PubMed ID: 7879050
    [No Abstract]   [Full Text] [Related]  

  • 6. Modes of action of FK506, cyclosporin A, and rapamycin.
    Morris R
    Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
    [No Abstract]   [Full Text] [Related]  

  • 7. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line.
    Wang SC; Zeevi A; Jordan ML; Simmons RL; Tweardy DJ
    Transplant Proc; 1991 Dec; 23(6):2920-2. PubMed ID: 1721312
    [No Abstract]   [Full Text] [Related]  

  • 8. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
    Hess DA; Bird IA; Almawi WY; Rieder MJ
    J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FK506 as an agonist to induce inhibition of interleukin 2 production.
    Bundick RV; Donald DK; Eady RP; Hutchinson R; Keogh RW; Schmidt JA; Wells E
    Transplantation; 1992 May; 53(5):1150-3. PubMed ID: 1374947
    [No Abstract]   [Full Text] [Related]  

  • 10. Transforming growth factor beta 1 inhibits interleukin-1-induced but enhances ionomycin-induced interferon-gamma production in a T cell lymphoma: comparison with the effects of rapamycin.
    Dumont FJ; Kastner CA
    J Cell Physiol; 1994 Jul; 160(1):141-53. PubMed ID: 8021294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressants FK506 and rapamycin have different effects on the biosynthesis of cytoplasmic actin during the early period of T cell activation.
    Miyamoto S; Safer B
    Biochem J; 1999 Dec; 344 Pt 3(Pt 3):803-12. PubMed ID: 10585867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells.
    Ogawa T; Tokuda M; Tomizawa K; Matsui H; Itano T; Konishi R; Nagahata S; Hatase O
    Biochem Biophys Res Commun; 1998 Aug; 249(1):226-30. PubMed ID: 9705862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin].
    Rondeau E
    Nephrologie; 1992; 13(3):137. PubMed ID: 1379348
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat.
    Yoshimura R; Yoshimura N; Ohmachi T; Nakatani T; Ohyama A; Miyao Y; Yamamoto K; Kishimoto T
    Transplant Proc; 1994 Oct; 26(5):2890. PubMed ID: 7524223
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia.
    Sharkey J; Butcher SP
    Nature; 1994 Sep; 371(6495):336-9. PubMed ID: 7522303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells.
    Ishizuka T; Sakata N; Johnson GL; Gelfand EW; Terada N
    Biochem Biophys Res Commun; 1997 Jan; 230(2):386-91. PubMed ID: 9016789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition by rapamycin of ornithine decarboxylase and epithelial cell proliferation in intestinal IEC-6 cells in culture.
    Seidel ER; Ragan VL
    Br J Pharmacol; 1997 Feb; 120(4):571-4. PubMed ID: 9051292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Categorizing receptor-signaling pathways with FK 506 and rapamycin.
    Hultsch T; Hohman RJ
    Transplant Proc; 1991 Dec; 23(6):2961-3. PubMed ID: 1721328
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclosporin A, FK506, and rapamycin: binding to immunophilins and biological action.
    Bierer BE
    Chem Immunol; 1994; 59():128-55. PubMed ID: 7524531
    [No Abstract]   [Full Text] [Related]  

  • 20. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function.
    Pelekanou V; Trezise AE; Moore AL; Kay JE
    Transplant Proc; 1991 Dec; 23(6):3200-1. PubMed ID: 1721408
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.